[
    [
        {
            "time": "2023-10-01",
            "original_text": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Gains",
                    "Lags Market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?",
            "features": {
                "keywords": [
                    "Roche",
                    "Blueprint",
                    "Deal",
                    "Eli Lilly",
                    "Cancer"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus",
            "features": {
                "keywords": [
                    "FDA",
                    "Fast-Track",
                    "Coronavirus",
                    "Vaccine",
                    "Stocks"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Pharmas restart drug trials after pandemic-related declines, Medidata finds",
            "features": {
                "keywords": [
                    "Pharmas",
                    "restart",
                    "drug trials",
                    "pandemic-related declines",
                    "Medidata"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharmas restart drug trials after pandemic-related declines, Medidata finds",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]